View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 11, 2016

Pluristem proceeds with Phase I trial of PLX-R18 to treat post-HCT, insufficient hematopoietic recovery

Israel-based drug development company Pluristem Therapeutics has advanced its Phase I trial of PLX-R18 cells in collaboration with a clinical research organisation (CRO) to treat insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT).

Israel-based drug development company Pluristem Therapeutics has advanced its Phase I trial of PLX-R18 cells in collaboration with a clinical research organisation (CRO) to treat insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT).

PLX-R18 cells eject proteins that regenerate bone marrow and allow it to redeem its ability to produce normal amounts of all three blood cell types.

The multi-centre, open-label, dose-escalating Phase I trial is designed to assess the safety of PLX-R18 cells, while being administered intramuscularly in 30 patients with incomplete hematopoietic recovery persistent for six months or more.

The trial received clearance from the US Food and Drug Administration (FDA) earlier this year and enrolment is planned to begin during the coming months.

"The CRO we chose has extensive experience working with leading pharmaceutical and biotech companies to successfully manage clinical trials."

Pluristem Chairman and CEO Zami Aberman said: “Data from this trial will inform the potential of PLX-R18 to treat a wide range of indications, including blood cancers and radiation therapy-related blood diseases.

“The CRO we chose has extensive experience working with leading pharmaceutical and biotech companies to successfully manage clinical trials.”

PLX-R18 can be administered without matching by using a standard syringe to inject the cells intramuscularly.

It is currently being studied in collaboration with the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to explore its efficacy in treating the hematological syndrome of ARS.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena